podophyllotoxin has been researched along with Canine Diseases in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Boyé, P; Floch, F; Fournel-Fleury, C; Serres, F; Tierny, D | 1 |
| Bemelmans, I; Bouchaert, E; Brel, V; Couffin, S; Ferré, P; Gomes, B; Guilbaud, N; Marchal, T; Nguyen, L; Pétain, A; Segaoula, Z; Serres, F; Thuru, X; Tierny, D | 1 |
2 trial(s) available for podophyllotoxin and Canine Diseases
| Article | Year |
|---|---|
Prognostic value of pretreatment plasma D-dimer level in dogs with intermediate to high-grade non-Hodgkin lymphoma.
Topics: Animals; Antineoplastic Agents; Dog Diseases; Dogs; Double-Blind Method; Etoposide; Female; Fibrin Fibrinogen Degradation Products; Lymphoma, Non-Hodgkin; Male; Organophosphorus Compounds; Podophyllotoxin; Prognosis; Thymidine Kinase | 2021 |
Phase I Clinical Pharmacology Study of F14512, a New Polyamine-Vectorized Anticancer Drug, in Naturally Occurring Canine Lymphoma.
Topics: Animals; Antineoplastic Agents; Biomarkers; Cell Line, Tumor; Dog Diseases; Dogs; Drug Evaluation, Preclinical; Female; Histones; Humans; Lymphoma; Male; Neoplasm Staging; Podophyllotoxin; Topoisomerase II Inhibitors; Treatment Outcome | 2015 |